Imidazol[1,5-c]quinazolines; a new class of GABA brain receptor
US6103731A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 11, 1998 |
| Grant date | Aug 15, 2000 |
| Priority date | — |
| Expiry date | Aug 11, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds of compounds of the formula: or the pharmaceutically acceptable nontoxic salts thereof wherein: PA1 X is oxygen, H.sub.2 or sulfur PA1 Y is hydrogen, or optionally substituted alkyl, alkenyl, (substituted)arylalkyl, aryl or heteroaryl, or a carbonyl group substituted with alkyl, cycloalkyl, aryl, or amino groups; PA1 W is alkyl, arylalkyl or heteroarylalkyl, where each aryl group is optionally substituted with up to two groups; or PA1 W is aryl, thienyl, pyridyl or heteroaryl, each of which is optionally substituted; and PA1 Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 independently represent nitrogen or C-R.sub.1 where R.sub.1 is hydrogen, halogen, hydroxy, amino, or phenyl or pyridyl optionally mono- or independently disubstituted with halogen, hydroxy, lower alkyl, or lower alkoxy, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.